NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 10:30AM ET
5.03
Dollar change
+0.30
Percentage change
6.30
%
Index- P/E- EPS (ttm)-22.45 Insider Own1.67% Shs Outstand1.81M Perf Week-31.87%
Market Cap9.11M Forward P/E- EPS next Y-13.08 Insider Trans181.77% Shs Float1.78M Perf Month-39.62%
Enterprise Value-2.43M PEG- EPS next Q-3.72 Inst Own9.68% Short Float3.86% Perf Quarter-44.52%
Income-24.54M P/S- EPS this Y58.04% Inst Trans- Short Ratio0.16 Perf Half Y-42.60%
Sales0.00M P/B1.00 EPS next Y14.81% ROA-83.27% Short Interest0.07M Perf YTD-43.94%
Book/sh5.03 P/C0.65 EPS next 5Y31.04% ROE-208.72% 52W High94.50 -94.68% Perf Year-93.43%
Cash/sh7.68 P/FCF- EPS past 3/5Y31.50% 40.27% ROIC-244.91% 52W Low4.36 15.33% Perf 3Y-95.91%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility18.27% 19.97% Perf 5Y-98.70%
Dividend TTM- EV/Sales- EPS Y/Y TTM81.80% Oper. Margin- ATR (14)1.48 Perf 10Y-99.99%
Dividend Ex-Date- Quick Ratio2.47 Sales Y/Y TTM- Profit Margin- RSI (14)34.45 Recom1.67
Dividend Gr. 3/5Y- - Current Ratio2.47 EPS Q/Q84.21% SMA20-46.60% Beta0.46 Target Price90.00
Payout- Debt/Eq0.05 Sales Q/Q- SMA50-41.68% Rel Volume1.51 Prev Close4.73
Employees11 LT Debt/Eq0.04 EarningsMay 13 BMO SMA200-78.75% Avg Volume439.10K Price5.03
IPOJun 14, 2005 Option/ShortNo / Yes EPS/Sales Surpr.14.29% - Trades Volume130,211 Change6.30%
Date Action Analyst Rating Change Price Target Change
Dec-05-24Resumed Ladenburg Thalmann Buy $13
Jul-01-20Initiated Oppenheimer Outperform
Jan-21-20Resumed ROTH Capital Buy $10
Sep-13-19Initiated ROTH Capital Buy
Dec-21-16Initiated Ladenburg Thalmann Buy $2.70
Jul-02-25 04:15PM
Jul-01-25 09:25AM
Jun-30-25 11:02AM
Jun-26-25 08:05AM
Jun-24-25 08:30AM
04:30PM Loading…
Jun-18-25 04:30PM
Jun-11-25 08:05AM
Jun-05-25 09:40AM
09:00AM
Jun-04-25 12:35PM
08:05AM
May-22-25 09:36AM
May-21-25 11:37AM
May-14-25 03:30AM
03:07AM
07:05AM Loading…
May-13-25 07:05AM
May-07-25 08:05AM
Apr-30-25 08:05AM
Apr-17-25 08:52AM
Mar-18-25 09:40AM
Mar-14-25 03:04AM
Mar-13-25 11:43PM
07:05AM
Mar-11-25 08:05AM
Mar-05-25 08:05AM
Feb-05-25 08:05AM
Jan-12-25 06:00PM
Dec-11-24 11:25AM
Dec-10-24 05:00PM
Nov-21-24 08:00AM
01:39AM Loading…
Nov-19-24 01:39AM
Nov-18-24 07:05AM
Nov-14-24 08:05AM
Nov-12-24 08:05AM
Nov-11-24 04:05PM
Nov-07-24 06:40AM
Nov-01-24 05:00PM
Aug-26-24 06:40AM
Aug-23-24 05:00PM
Aug-13-24 06:40AM
Aug-08-24 05:15PM
04:05PM
Jul-23-24 06:40AM
Jul-22-24 06:40AM
Jun-27-24 06:40AM
May-29-24 06:40AM
May-15-24 08:18AM
03:43AM
03:02AM
May-14-24 10:53AM
06:40AM
May-08-24 06:40AM
May-07-24 06:40AM
Mar-28-24 10:33AM
Mar-27-24 10:09PM
10:53AM
06:40AM
Mar-20-24 06:40AM
Mar-14-24 08:52AM
Mar-04-24 06:40AM
Feb-07-24 06:40AM
Jan-30-24 06:40AM
Jan-25-24 06:40AM
Jan-22-24 06:40AM
Jan-16-24 06:40AM
Jan-12-24 06:44AM
Jan-11-24 06:40AM
Jan-08-24 08:37AM
06:40AM
06:30AM
Jan-03-24 08:30AM
Dec-19-23 08:30AM
Dec-12-23 08:30AM
Dec-05-23 08:30AM
Nov-04-23 12:36PM
Nov-02-23 07:30AM
Oct-25-23 08:00AM
Oct-24-23 08:00AM
Oct-17-23 08:00AM
Oct-02-23 06:35AM
Sep-18-23 08:40AM
Sep-11-23 06:30AM
Sep-05-23 08:21AM
Aug-14-23 08:40AM
Jun-30-23 09:40AM
Jun-28-23 08:30AM
Jun-12-23 08:30AM
May-04-23 09:22AM
08:40AM
Mar-09-23 08:40AM
Mar-08-23 04:05PM
Feb-28-23 08:30AM
Feb-15-23 08:30AM
Nov-30-22 08:30AM
Nov-21-22 08:30AM
Nov-16-22 08:30AM
Nov-03-22 08:30AM
Oct-25-22 04:30PM
Oct-21-22 08:30AM
Sep-22-22 08:30AM
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on June 24, 1996 and is headquartered in Florham Park, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CARUSO JAMES VChief Executive OfficerJul 02 '25Buy4.9910,00049,90011,638Jul 03 08:02 AM
Longcor JarrodChief Operating OfficerJul 02 '25Buy4.9910,00049,90012,768Jul 03 08:01 AM
Kolean Chad JChief Financial OfficerJul 02 '25Buy4.995,00024,9506,418Jul 03 08:00 AM
Longcor JarrodChief Operating OfficerJan 10 '25Buy0.2830,0008,40083,141Mar 12 09:44 PM